{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:52:19Z","timestamp":1786121539728,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 HL139420"],"award-info":[{"award-number":["P01 HL139420"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007109","name":"University of Ferrara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtha.2026.04.027","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:35:49Z","timestamp":1778283349000},"page":"2789-2800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia"],"prefix":"10.1016","volume":"24","author":[{"given":"Rebecca","family":"Tarantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Pinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney M.","family":"Camire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-2694","authenticated-orcid":false,"given":"Alessio","family":"Branchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.04.027_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11239-021-02456-w","article-title":"Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics","volume":"52","author":"Camire","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2026.04.027_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jth.12217","article-title":"The transition of prothrombin to thrombin","volume":"11","author":"Krishnaswamy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.04.027_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH13-03-0213","article-title":"Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin","volume":"110","author":"Metzner","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib6","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.04.027_bib7","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.027_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.12985","article-title":"Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(\u00ae) in patients with severe haemophilia A","volume":"22","author":"Klamroth","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.04.027_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.12766","article-title":"Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A","volume":"22","author":"Nolan","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.04.027_bib10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.027_bib11","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/hae.13875","article-title":"PEGylated biologics in haemophilia treatment: current understanding of their long-term safety","volume":"26","author":"Baumann","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.04.027_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0580","article-title":"An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics","volume":"12","author":"Bern","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2026.04.027_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.17559","article-title":"Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity","volume":"194","author":"Lombardi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.027_bib14","first-page":"2436","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.027_bib15","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1038\/s41467-025-62955-9","article-title":"Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties","volume":"16","author":"Aaen","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2026.04.027_bib16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.04.027_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000911","article-title":"Nonfactor therapies for hemophilia","volume":"7","author":"Young","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2026.04.027_bib18","first-page":"1334","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.027_bib19","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.jtha.2025.06.013","article-title":"A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants","volume":"23","author":"Sambe","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib20","first-page":"2902","article-title":"Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties","volume":"110","author":"Van Thillo","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.027_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2007.01594.x","article-title":"Factor VIII inhibitor bypassing activity (FEIBA)\u2014addressing safety issues","volume":"14","author":"Aledort","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.04.027_bib22","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s00277-023-05287-2","article-title":"Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven\u00ae, in the treatment of haemophilia and rare bleeding disorders","volume":"103","author":"Shima","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2026.04.027_bib23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene therapy for hemophilia\u2014from basic science to first approvals of \u201cone-and-done\u201d therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2026.04.027_bib24","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0049-3848(16)30360-7","article-title":"Bioengineering factor Xa to treat bleeding","volume":"141","author":"Camire","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.027_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.027_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.13543","article-title":"Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A","volume":"15","author":"Nguyen","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib27","doi-asserted-by":"crossref","first-page":"14322","DOI":"10.1021\/bi001074q","article-title":"Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide","volume":"39","author":"Camire","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2026.04.027_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.thromres.2018.11.007","article-title":"The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies","volume":"173","author":"Ferrarese","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.027_bib29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/jth.13034","article-title":"The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X","volume":"13","author":"Branchini","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib30","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","article-title":"Evidence for factor IX-independent roles for factor XIa in blood coagulation","volume":"11","author":"Matafonov","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib31","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtha.2026.04.027_bib32","doi-asserted-by":"crossref","first-page":"W24","DOI":"10.1093\/nar\/gkx346","article-title":"BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes","volume":"45","author":"Jespersen","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtha.2026.04.027_bib33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1042\/bj1850647","article-title":"Pathways in the activation of human coagulation factor X","volume":"185","author":"Mertens","year":"1980","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2026.04.027_bib34","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1016\/S0021-9258(19)41330-6","article-title":"The activation of coagulation factor X. Identity of cleavage sites in the alternative activation pathways and characterization of the COOH-terminal peptide","volume":"250","author":"Jesty","year":"1975","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.04.027_bib35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.027_bib36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-2000-8457","article-title":"Pharmacokinetics of recombinant activated factor VII (rFVIIa)","volume":"26","author":"Erhardtsen","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib37","first-page":"491","article-title":"A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo","volume":"69","author":"Giles","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.027_bib38","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1055\/s-0037-1613347","article-title":"A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo","volume":"88","author":"Himmelspach","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0049-3848(80)90070-5","article-title":"The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits","volume":"17","author":"Giles","year":"1980","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.027_bib40","doi-asserted-by":"crossref","first-page":"21864","DOI":"10.1016\/S0021-9258(18)54717-7","article-title":"Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma","volume":"266","author":"Tans","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.04.027_bib41","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1016\/S0021-9258(17)39811-3","article-title":"Inhibition of human activated factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma","volume":"259","author":"Gitel","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.04.027_bib42","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/j.1460-2075.1989.tb08511.x","article-title":"The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment","volume":"8","author":"Bode","year":"1989","journal-title":"EMBO J"},{"key":"10.1016\/j.jtha.2026.04.027_bib43","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1074\/jbc.M802205200","article-title":"The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly","volume":"283","author":"Toso","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.04.027_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2015-03-634329","article-title":"Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity","volume":"126","author":"Ivanciu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.027_bib45","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nbt.1995","article-title":"A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia","volume":"29","author":"Ivanciu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2026.04.027_bib46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nm.4149","article-title":"A rapid pro-hemostatic approach to overcome direct oral anticoagulants","volume":"22","author":"Thalji","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2026.04.027_bib47","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.xphs.2017.03.035","article-title":"Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and interspecies scaling of recombinant human coagulation factor XaI16L","volume":"106","author":"Parng","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jtha.2026.04.027_bib48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.13673","article-title":"Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)","volume":"15","author":"Parsons-Rich","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.027_bib49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/STROKEAHA.120.029789","article-title":"Phase 1b study to evaluate safety, tolerability, and maximum tolerated dose of PF-05230907 for intracerebral hemorrhage","volume":"52","author":"Silva Blas","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.04.027_bib50","doi-asserted-by":"crossref","first-page":"41352","DOI":"10.1074\/jbc.M507846200","article-title":"Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas","volume":"280","author":"Louvain-Quintard","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.04.027_bib51","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3324\/haematol.2019.219865","article-title":"A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A","volume":"105","author":"Abache","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.027_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2021.102570","article-title":"Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent","volume":"89","author":"Ebert","year":"2021","journal-title":"Blood Cells Mol Dis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:21:58Z","timestamp":1786080118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1538783626002783"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}